EASIX for Prediction of Outcome in Hospitalized SARS-CoV-2 Infected Patients

The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has evoked a pandemic that challenges public health-care systems worldwide. Endothelial cell dysfunction plays a key role in pathophysiology, and simple prognosticators may help to o...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Frontiers in immunology Ročník 12; s. 634416
Hlavní autoři: Luft, Thomas, Wendtner, Clemens-Martin, Kosely, Florentina, Radujkovic, Aleksandar, Benner, Axel, Korell, Felix, Kihm, Lars, Bauer, Matthias F., Dreger, Peter, Merle, Uta
Médium: Journal Article
Jazyk:angličtina
Vydáno: Switzerland Frontiers Media S.A 23.06.2021
Témata:
ISSN:1664-3224, 1664-3224
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has evoked a pandemic that challenges public health-care systems worldwide. Endothelial cell dysfunction plays a key role in pathophysiology, and simple prognosticators may help to optimize allocation of limited resources. Endothelial activation and stress index (EASIX) is a validated predictor of endothelial complications and outcome after allogeneic stem cell transplantation. Aim of this study was to test if EASIX could predict life-threatening complications in patients with COVID-19. SARS-CoV-2-positive, hospitalized patients were enrolled onto a prospective non-interventional register study (n=100). Biomarkers were assessed at hospital admission. Primary endpoint was severe course of disease (mechanical ventilation and/or death, V/D). Results were validated in 126 patients treated in two independent institutions. EASIX at admission was a strong predictor of severe course of the disease (odds ratio for a two-fold change 3.4, 95%CI 1.8-6.3, p<0.001), time to V/D (hazard ratio (HR) for a two-fold change 2.0, 95%CI 1.5-2.6, p<0.001) as well as survival (HR for a two-fold change 1.7, 95%CI 1.2-2.5, p=0.006). The effect was retained in multivariable analysis adjusting for age, gender, and comorbidities and could be validated in the independent cohort. At hospital admission EASIX correlated with increased suppressor of tumorigenicity-2, soluble thrombomodulin, angiopoietin-2, CXCL8, CXCL9 and interleukin-18, but not interferon-alpha. EASIX is a validated predictor of COVID19 outcome and an easy-to-access tool to segregate patients in need for intensive surveillance.
AbstractList The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has evoked a pandemic that challenges public health-care systems worldwide. Endothelial cell dysfunction plays a key role in pathophysiology, and simple prognosticators may help to optimize allocation of limited resources. Endothelial activation and stress index (EASIX) is a validated predictor of endothelial complications and outcome after allogeneic stem cell transplantation. Aim of this study was to test if EASIX could predict life-threatening complications in patients with COVID-19.BACKGROUNDThe coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has evoked a pandemic that challenges public health-care systems worldwide. Endothelial cell dysfunction plays a key role in pathophysiology, and simple prognosticators may help to optimize allocation of limited resources. Endothelial activation and stress index (EASIX) is a validated predictor of endothelial complications and outcome after allogeneic stem cell transplantation. Aim of this study was to test if EASIX could predict life-threatening complications in patients with COVID-19.SARS-CoV-2-positive, hospitalized patients were enrolled onto a prospective non-interventional register study (n=100). Biomarkers were assessed at hospital admission. Primary endpoint was severe course of disease (mechanical ventilation and/or death, V/D). Results were validated in 126 patients treated in two independent institutions.METHODSSARS-CoV-2-positive, hospitalized patients were enrolled onto a prospective non-interventional register study (n=100). Biomarkers were assessed at hospital admission. Primary endpoint was severe course of disease (mechanical ventilation and/or death, V/D). Results were validated in 126 patients treated in two independent institutions.EASIX at admission was a strong predictor of severe course of the disease (odds ratio for a two-fold change 3.4, 95%CI 1.8-6.3, p<0.001), time to V/D (hazard ratio (HR) for a two-fold change 2.0, 95%CI 1.5-2.6, p<0.001) as well as survival (HR for a two-fold change 1.7, 95%CI 1.2-2.5, p=0.006). The effect was retained in multivariable analysis adjusting for age, gender, and comorbidities and could be validated in the independent cohort. At hospital admission EASIX correlated with increased suppressor of tumorigenicity-2, soluble thrombomodulin, angiopoietin-2, CXCL8, CXCL9 and interleukin-18, but not interferon-alpha.RESULTSEASIX at admission was a strong predictor of severe course of the disease (odds ratio for a two-fold change 3.4, 95%CI 1.8-6.3, p<0.001), time to V/D (hazard ratio (HR) for a two-fold change 2.0, 95%CI 1.5-2.6, p<0.001) as well as survival (HR for a two-fold change 1.7, 95%CI 1.2-2.5, p=0.006). The effect was retained in multivariable analysis adjusting for age, gender, and comorbidities and could be validated in the independent cohort. At hospital admission EASIX correlated with increased suppressor of tumorigenicity-2, soluble thrombomodulin, angiopoietin-2, CXCL8, CXCL9 and interleukin-18, but not interferon-alpha.EASIX is a validated predictor of COVID19 outcome and an easy-to-access tool to segregate patients in need for intensive surveillance.CONCLUSIONEASIX is a validated predictor of COVID19 outcome and an easy-to-access tool to segregate patients in need for intensive surveillance.
The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has evoked a pandemic that challenges public health-care systems worldwide. Endothelial cell dysfunction plays a key role in pathophysiology, and simple prognosticators may help to optimize allocation of limited resources. Endothelial activation and stress index (EASIX) is a validated predictor of endothelial complications and outcome after allogeneic stem cell transplantation. Aim of this study was to test if EASIX could predict life-threatening complications in patients with COVID-19. SARS-CoV-2-positive, hospitalized patients were enrolled onto a prospective non-interventional register study (n=100). Biomarkers were assessed at hospital admission. Primary endpoint was severe course of disease (mechanical ventilation and/or death, V/D). Results were validated in 126 patients treated in two independent institutions. EASIX at admission was a strong predictor of severe course of the disease (odds ratio for a two-fold change 3.4, 95%CI 1.8-6.3, p<0.001), time to V/D (hazard ratio (HR) for a two-fold change 2.0, 95%CI 1.5-2.6, p<0.001) as well as survival (HR for a two-fold change 1.7, 95%CI 1.2-2.5, p=0.006). The effect was retained in multivariable analysis adjusting for age, gender, and comorbidities and could be validated in the independent cohort. At hospital admission EASIX correlated with increased suppressor of tumorigenicity-2, soluble thrombomodulin, angiopoietin-2, CXCL8, CXCL9 and interleukin-18, but not interferon-alpha. EASIX is a validated predictor of COVID19 outcome and an easy-to-access tool to segregate patients in need for intensive surveillance.
BackgroundThe coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has evoked a pandemic that challenges public health-care systems worldwide. Endothelial cell dysfunction plays a key role in pathophysiology, and simple prognosticators may help to optimize allocation of limited resources. Endothelial activation and stress index (EASIX) is a validated predictor of endothelial complications and outcome after allogeneic stem cell transplantation. Aim of this study was to test if EASIX could predict life-threatening complications in patients with COVID-19.MethodsSARS-CoV-2-positive, hospitalized patients were enrolled onto a prospective non-interventional register study (n=100). Biomarkers were assessed at hospital admission. Primary endpoint was severe course of disease (mechanical ventilation and/or death, V/D). Results were validated in 126 patients treated in two independent institutions.ResultsEASIX at admission was a strong predictor of severe course of the disease (odds ratio for a two-fold change 3.4, 95%CI 1.8-6.3, p<0.001), time to V/D (hazard ratio (HR) for a two-fold change 2.0, 95%CI 1.5-2.6, p<0.001) as well as survival (HR for a two-fold change 1.7, 95%CI 1.2-2.5, p=0.006). The effect was retained in multivariable analysis adjusting for age, gender, and comorbidities and could be validated in the independent cohort. At hospital admission EASIX correlated with increased suppressor of tumorigenicity-2, soluble thrombomodulin, angiopoietin-2, CXCL8, CXCL9 and interleukin-18, but not interferon-alpha.ConclusionEASIX is a validated predictor of COVID19 outcome and an easy-to-access tool to segregate patients in need for intensive surveillance.
Author Benner, Axel
Bauer, Matthias F.
Dreger, Peter
Kosely, Florentina
Wendtner, Clemens-Martin
Radujkovic, Aleksandar
Luft, Thomas
Merle, Uta
Korell, Felix
Kihm, Lars
AuthorAffiliation 2 Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilians University (LMU) , Munich , Germany
7 Department of Internal Medicine IV, University of Heidelberg , Heidelberg , Germany
1 Department of Internal Medicine V, University of Heidelberg , Heidelberg , Germany
4 Division of Biostatistics, German Cancer Research Center , Heidelberg , Germany
6 Institute of Laboratory Diagnostics, Hygiene and Transfusion Medicine, Hospital Ludwigshafen , Ludwigshafen , Germany
3 Medical Department B, Hospital Ludwigshafen , Ludwigshafen , Germany
5 Department of Internal Medicine I, University of Heidelberg , Heidelberg , Germany
AuthorAffiliation_xml – name: 2 Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilians University (LMU) , Munich , Germany
– name: 4 Division of Biostatistics, German Cancer Research Center , Heidelberg , Germany
– name: 7 Department of Internal Medicine IV, University of Heidelberg , Heidelberg , Germany
– name: 1 Department of Internal Medicine V, University of Heidelberg , Heidelberg , Germany
– name: 3 Medical Department B, Hospital Ludwigshafen , Ludwigshafen , Germany
– name: 5 Department of Internal Medicine I, University of Heidelberg , Heidelberg , Germany
– name: 6 Institute of Laboratory Diagnostics, Hygiene and Transfusion Medicine, Hospital Ludwigshafen , Ludwigshafen , Germany
Author_xml – sequence: 1
  givenname: Thomas
  surname: Luft
  fullname: Luft, Thomas
– sequence: 2
  givenname: Clemens-Martin
  surname: Wendtner
  fullname: Wendtner, Clemens-Martin
– sequence: 3
  givenname: Florentina
  surname: Kosely
  fullname: Kosely, Florentina
– sequence: 4
  givenname: Aleksandar
  surname: Radujkovic
  fullname: Radujkovic, Aleksandar
– sequence: 5
  givenname: Axel
  surname: Benner
  fullname: Benner, Axel
– sequence: 6
  givenname: Felix
  surname: Korell
  fullname: Korell, Felix
– sequence: 7
  givenname: Lars
  surname: Kihm
  fullname: Kihm, Lars
– sequence: 8
  givenname: Matthias F.
  surname: Bauer
  fullname: Bauer, Matthias F.
– sequence: 9
  givenname: Peter
  surname: Dreger
  fullname: Dreger, Peter
– sequence: 10
  givenname: Uta
  surname: Merle
  fullname: Merle, Uta
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34248931$$D View this record in MEDLINE/PubMed
BookMark eNp1kV9rFDEUxYNUbK39AL7IPPoy6-T_5EVYltouLLS4Kr6FJHNTU2YmazIj6KdvtttKK5iXXG7u-R1uzmt0NMYREHqLmwWlrfrgwzDMC9IQvBCUMSxeoBMsBKspIezoSX2MznK-bcphilLKX6FjyghrFcUnaHO-3K6_Vz6m6jpBF9wU4lhFX13Nk4sDVGGsLmPehcn04Q901Xb5eVuv4reaVOvRg5tK79pMAcYpv0EvvekznD3cp-jrp_Mvq8t6c3WxXi03tWOCTzV2tvGdaSVmRkhJgFBlnZCKWcIb6YkChw0tBReNFeAsptZwjlsswYKgp2h94HbR3OpdCoNJv3U0Qd83YrrRJk3B9aCZbbkxVrUee-alsi3uusYS6TgIx3hhfTywdrMdoHNlj2T6Z9DnL2P4oW_iL90SgTFnBfD-AZDizxnypIeQHfS9GSHOWRPOG0GJVHuvd0-9_po8xlEG5GHApZhzAq9d-fh9JMU69Bo3ep-9vs9e77PXh-yLEv-jfIT_X3MHVaKxuw
CitedBy_id crossref_primary_10_3390_ijms23158230
crossref_primary_10_1515_cclm_2023_1017
crossref_primary_10_3390_jcm10163534
crossref_primary_10_1007_s00392_024_02534_y
crossref_primary_10_1111_bjh_18596
crossref_primary_10_1136_jitc_2023_007635
crossref_primary_10_1038_s41409_021_01500_w
crossref_primary_10_3389_fmed_2025_1622944
crossref_primary_10_3389_fmed_2024_1498148
crossref_primary_10_3390_jcm14082857
crossref_primary_10_1016_j_ijcard_2025_133566
crossref_primary_10_2217_pme_2021_0077
crossref_primary_10_3389_fmed_2021_736028
crossref_primary_10_1007_s00134_022_06676_3
crossref_primary_10_1161_JAHA_125_041059
crossref_primary_10_3390_v15071430
crossref_primary_10_1186_s12882_024_03887_2
crossref_primary_10_1186_s12879_025_11363_x
crossref_primary_10_1007_s00277_024_05640_z
crossref_primary_10_3390_covid5060089
crossref_primary_10_1007_s00011_022_01596_w
crossref_primary_10_1038_s41598_025_95122_7
crossref_primary_10_1111_eci_13883
crossref_primary_10_3390_jcm12072553
crossref_primary_10_1080_10408363_2023_2232010
crossref_primary_10_1007_s00392_025_02715_3
crossref_primary_10_1371_journal_pone_0304960
crossref_primary_10_1007_s00392_024_02566_4
crossref_primary_10_1111_aji_70167
crossref_primary_10_1007_s12288_022_01623_0
crossref_primary_10_1182_bloodadvances_2022008617
crossref_primary_10_3389_fimmu_2022_877477
crossref_primary_10_1080_16078454_2025_2519974
crossref_primary_10_1016_j_jcyt_2023_10_008
crossref_primary_10_3390_jpm12071022
Cites_doi 10.1016/j.cell.2020.02.052
10.1016/j.ebiom.2019.10.024
10.1111/j.0006-341X.2000.00337.x
10.1002/jmv.25915
10.1002/bimj.200610301
10.1038/s41408-019-0247-z
10.1016/j.ijid.2020.03.017
10.1182/blood-2011-02-334821
10.1186/s13054-020-2833-7
10.3324/haematol.10699
10.1038/s41577-020-0343-0
10.1093/cvr/cvaa106
10.1016/j.thromres.2020.04.014
10.1056/NEJMoa1213299
10.1016/j.jacc.2008.09.027
10.1016/j.eclinm.2020.100449
10.1016/j.amjcard.2015.01.034
10.1016/j.jacc.2020.04.031
10.1038/s41409-019-0703-1
10.3390/cancers12102789
10.1182/bloodadvances.2019032268
10.1007/s10456-020-09730-0
10.1016/S2352-3026(17)30108-4
10.1038/bmt.2017.119
10.1093/infdis/jiaa528
10.1161/CIRCULATIONAHA.120.047549
10.1161/CIRCULATIONAHA.120.047419
10.3324/haematol.2011.061051
10.1093/cvr/cvaa230
10.1186/s12885-020-07317-y
10.3389/fimmu.2021.648004
10.1016/S0140-6736(20)31129-6
10.1016/j.bbmt.2020.01.028
10.1007/s002770050364
10.1001/jamacardio.2020.0950
10.1016/S0140-6736(20)30566-3
10.1101/2020.04.29.20085878
10.1001/jama.2020.1585
10.1177/2045894020966547
10.1016/S0140-6736(20)30937-5
10.1016/S0140-6736(20)31103-X
10.1038/s41408-021-00434-2
10.1111/j.1541-0420.2008.00995.x
10.1186/s40001-020-00432-3
10.1080/09537104.2020.1762852
10.7326/M20-0504
10.1016/j.bbmt.2012.09.018
10.1017/S095026882000179X
10.1515/cclm-2020-1062
10.1002/bimj.200810443
ContentType Journal Article
Copyright Copyright © 2021 Luft, Wendtner, Kosely, Radujkovic, Benner, Korell, Kihm, Bauer, Dreger and Merle.
Copyright © 2021 Luft, Wendtner, Kosely, Radujkovic, Benner, Korell, Kihm, Bauer, Dreger and Merle 2021 Luft, Wendtner, Kosely, Radujkovic, Benner, Korell, Kihm, Bauer, Dreger and Merle
Copyright_xml – notice: Copyright © 2021 Luft, Wendtner, Kosely, Radujkovic, Benner, Korell, Kihm, Bauer, Dreger and Merle.
– notice: Copyright © 2021 Luft, Wendtner, Kosely, Radujkovic, Benner, Korell, Kihm, Bauer, Dreger and Merle 2021 Luft, Wendtner, Kosely, Radujkovic, Benner, Korell, Kihm, Bauer, Dreger and Merle
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.3389/fimmu.2021.634416
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
ExternalDocumentID oai_doaj_org_article_4b85aab98f1f4f79b81dd0b27c5e6c45
PMC8261154
34248931
10_3389_fimmu_2021_634416
Genre Journal Article
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
ACXDI
CGR
CUY
CVF
ECM
EIF
IAO
IEA
IHR
IHW
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c465t-1cb0fda8714a6772e239bc6794b2507f29ec1a37f2560b6ecb13ba551817ebe63
IEDL.DBID DOA
ISICitedReferencesCount 41
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000670252800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1664-3224
IngestDate Fri Oct 03 12:52:58 EDT 2025
Thu Aug 21 14:12:37 EDT 2025
Wed Oct 01 13:47:25 EDT 2025
Thu Jan 02 22:56:00 EST 2025
Sat Nov 29 02:07:00 EST 2025
Tue Nov 18 22:44:25 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords angiopoietin-2 (Ang-2)
soluble thrombomodulin
prediction of outcome
endothelial activation and stress index
suppressor of tumorigenicity 2 (ST2)
EASIX
SARS-CoV2 (COVID- 19)
Language English
License Copyright © 2021 Luft, Wendtner, Kosely, Radujkovic, Benner, Korell, Kihm, Bauer, Dreger and Merle.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c465t-1cb0fda8714a6772e239bc6794b2507f29ec1a37f2560b6ecb13ba551817ebe63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Helena Stabile, Sapienza University of Rome, Italy
This article was submitted to Cytokines and Soluble Mediators in Immunity, a section of the journal Frontiers in Immunology
Reviewed by: Saikat Majumder, University of Pittsburgh, United States; Tatiani Uceli Maioli, Federal University of Minas Gerais, Brazil
OpenAccessLink https://doaj.org/article/4b85aab98f1f4f79b81dd0b27c5e6c45
PMID 34248931
PQID 2550632795
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_4b85aab98f1f4f79b81dd0b27c5e6c45
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8261154
proquest_miscellaneous_2550632795
pubmed_primary_34248931
crossref_citationtrail_10_3389_fimmu_2021_634416
crossref_primary_10_3389_fimmu_2021_634416
PublicationCentury 2000
PublicationDate 2021-06-23
PublicationDateYYYYMMDD 2021-06-23
PublicationDate_xml – month: 06
  year: 2021
  text: 2021-06-23
  day: 23
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in immunology
PublicationTitleAlternate Front Immunol
PublicationYear 2021
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Radujkovic (B32) 2019; 49
Luft (B24) 2020; 55
Liu (B18) 2020; 142
Heagerty (B38) 2000; 56
Dai (B30) 2021; 11
Bikdeli (B9) 2020; 75
Shouval (B25) 2019; 3
Gerds (B37) 2006; 48
Varma (B26) 2020; 3
Wang (B2) 2020; 323
Campbell (B17) 2020
Luft (B23) 2017; 4
Dietrich (B29) 2013; 19
Viner (B8) 2020; 395
Ciceri (B15) 2020; 22
Radujkovic (B31) 2020; 12
Yang (B5) 2020; 94
Shi (B35) 2020; 24
Guzik (B3) 2020; 116
Smadja (B16) 2020; 23
Shi (B4) 2020; 5
Paniz-Mondolfi (B11) 2020; 92
Gerds (B36) 2008; 50
Salamanna (B43) 2020; 31
Ruutu (B21) 2007; 92
Zeisbrich (B20) 2017; 52
Pascual-Figal (B47) 2015; 115
Mancuso (B51) 2020; 18
Evans (B52) 2020; 116
Ou (B41) 2020; 148
Luft (B19) 2011; 118
Song (B28) 2020; 20
Contoli (B33) 2021; 12
Panteghini (B42) 2020; 58
Vander Lugt (B49) 2013; 369
Jiang (B22) 2020; 92
Pine (B34) 2020; 10
Hothorn (B39) 2008; 64
Andrulis (B48) 2012; 97
Lauer (B1) 2020; 172
Zhou (B6) 2020; 395
Verdoni (B7) 2020; 395
Varga (B13) 2020; 35
Bartunek (B46) 2008; 52
Teuwen (B12) 2020; 20
Hoffmann (B14) 2020; 181
Nurnberger (B45) 1998; 76
Wendel Garcia (B44) 2020; 25
Guervilly (B50) 2020; 222
Escher (B10) 2020; 190
Merz (B27) 2019; 9
Ghahramani (B40) 2020; 25
References_xml – volume: 181
  start-page: 271
  year: 2020
  ident: B14
  article-title: SARS-Cov-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
  publication-title: Cell
  doi: 10.1016/j.cell.2020.02.052
– volume: 49
  year: 2019
  ident: B32
  article-title: Interleukin-18 and Outcome After Allogeneic Stem Cell Transplantation: A Retrospective Cohort Study
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2019.10.024
– volume: 56
  year: 2000
  ident: B38
  article-title: Time-Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
  publication-title: Biometrics
  doi: 10.1111/j.0006-341X.2000.00337.x
– volume: 92
  start-page: 699
  year: 2020
  ident: B11
  article-title: Central Nervous System Involvement by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-Cov-2)
  publication-title: J Med Virol
  doi: 10.1002/jmv.25915
– volume: 48
  year: 2006
  ident: B37
  article-title: Consistent Estimation of the Expected Brier Score in General Survival Models With Right-Censored Event Times
  publication-title: Biom J
  doi: 10.1002/bimj.200610301
– volume: 9
  start-page: 85
  year: 2019
  ident: B27
  article-title: EASIX for Prediction of Survival in Lower-Risk Myelodysplastic Syndromes
  publication-title: Blood Cancer J
  doi: 10.1038/s41408-019-0247-z
– volume: 94
  year: 2020
  ident: B5
  article-title: Prevalence of Comorbidities and Its Effects in Coronavirus Disease 2019 Patients: A Systematic Review and Meta-Analysis
  publication-title: Int J Infect Dis
  doi: 10.1016/j.ijid.2020.03.017
– volume: 118
  year: 2011
  ident: B19
  article-title: Steroid-Refractory GVHD: T-Cell Attack Within a Vulnerable Endothelial System
  publication-title: Blood
  doi: 10.1182/blood-2011-02-334821
– volume: 24
  start-page: 108
  year: 2020
  ident: B35
  article-title: Host Susceptibility to Severe COVID-19 and Establishment of a Host Risk Score: Findings of 487 Cases Outside Wuhan
  publication-title: Crit Care
  doi: 10.1186/s13054-020-2833-7
– volume: 92
  start-page: 95
  year: 2007
  ident: B21
  article-title: Diagnostic Criteria for Hematopoietic Stem Cell Transplant-Associated Microangiopathy: Results of a Consensus Process by an International Working Group
  publication-title: Haematologica
  doi: 10.3324/haematol.10699
– volume: 20
  year: 2020
  ident: B12
  article-title: Covid-19: The Vasculature Unleashed
  publication-title: Nat Rev Immunol
  doi: 10.1038/s41577-020-0343-0
– volume: 116
  year: 2020
  ident: B3
  article-title: Covid-19 and the Cardiovascular System: Implications for Risk Assessment, Diagnosis, and Treatment Options
  publication-title: Cardiovasc Res
  doi: 10.1093/cvr/cvaa106
– volume: 190
  start-page: 62
  year: 2020
  ident: B10
  article-title: Severe COVID-19 Infection Associated With Endothelial Activation
  publication-title: Thromb Res
  doi: 10.1016/j.thromres.2020.04.014
– volume: 369
  year: 2013
  ident: B49
  article-title: ST2 as a Marker for Risk of Therapy-Resistant Graft-Versus-Host Disease and Death
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1213299
– volume: 52
  year: 2008
  ident: B46
  article-title: Nonmyocardial Production of ST2 Protein in Human Hypertrophy and Failure Is Related to Diastolic Load
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2008.09.027
– volume: 25
  start-page: 100449
  year: 2020
  ident: B44
  article-title: Prognostic Factors Associated With Mortality Risk and Disease Progression in 639 Critically Ill Patients With COVID-19 in Europe: Initial Report of the International RISC-19-ICU Prospective Observational Cohort
  publication-title: EClinicalMedicine
  doi: 10.1016/j.eclinm.2020.100449
– volume: 115
  start-page: 3B
  year: 2015
  ident: B47
  article-title: The Biology of ST2: The International St2 Consensus Panel
  publication-title: Am J Cardiol
  doi: 10.1016/j.amjcard.2015.01.034
– volume: 75
  year: 2020
  ident: B9
  article-title: Covid-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2020.04.031
– volume: 55
  year: 2020
  ident: B24
  article-title: EASIX and Mortality After Allogeneic Stem Cell Transplantation
  publication-title: Bone Marrow Transplant
  doi: 10.1038/s41409-019-0703-1
– volume: 12
  start-page: 2789
  year: 2020
  ident: B31
  article-title: Interleukin-18 and Hematopoietic Recovery After Allogeneic Stem Cell Transplantation
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers12102789
– volume: 3
  year: 2019
  ident: B25
  article-title: External Validation and Comparison of Multiple Prognostic Scores in Allogeneic Hematopoietic Stem Cell Transplantation
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2019032268
– volume: 23
  year: 2020
  ident: B16
  article-title: Angiopoietin-2 as a Marker of Endothelial Activation Is a Good Predictor Factor for Intensive Care Unit Admission of COVID-19 Patients
  publication-title: Angiogenesis
  doi: 10.1007/s10456-020-09730-0
– volume: 4
  year: 2017
  ident: B23
  article-title: EASIX in Patients With Acute Graft-Versus-Host Disease: A Retrospective Cohort Analysis
  publication-title: Lancet Haematol
  doi: 10.1016/S2352-3026(17)30108-4
– volume: 52
  year: 2017
  ident: B20
  article-title: Transplant-Associated Thrombotic Microangiopathy Is an Endothelial Complication Associated With Refractoriness of Acute GvHD
  publication-title: Bone Marrow Transplant
  doi: 10.1038/bmt.2017.119
– volume: 22
  start-page: 284
  year: 2020
  ident: B15
  article-title: Microvascular COVID-19 Lung Vessels Obstructive Thromboinflammatory Syndrome (MicroCLOTS): An Atypical Acute Respiratory Distress Syndrome Working Hypothesis
  publication-title: Crit Care Resusc
– volume: 222
  year: 2020
  ident: B50
  article-title: Circulating Endothelial Cells as a Marker of Endothelial Injury in Severe Covid-19
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiaa528
– volume: 142
  start-page: 68
  year: 2020
  ident: B18
  article-title: The Science Underlying COVID-19: Implications for the Cardiovascular System
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.120.047549
– year: 2020
  ident: B17
  article-title: Will Complement Inhibition be the New Target in Treating Covid-19 Related Systemic Thrombosis
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.120.047419
– volume: 97
  year: 2012
  ident: B48
  article-title: Loss of Endothelial Thrombomodulin Predicts Response to Steroid Therapy and Survival in Acute Intestinal Graft-Versus-Host Disease
  publication-title: Haematologica
  doi: 10.3324/haematol.2011.061051
– volume: 116
  year: 2020
  ident: B52
  article-title: Endothelial Dysfunction in COVID-19: A Position Paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science
  publication-title: Cardiovasc Res
  doi: 10.1093/cvr/cvaa230
– volume: 20
  start-page: 803
  year: 2020
  ident: B28
  article-title: Endothelial Activation and Stress Index (EASIX) Is a Reliable Predictor for Overall Survival in Patients With Multiple Myeloma
  publication-title: BMC Cancer
  doi: 10.1186/s12885-020-07317-y
– volume: 12
  year: 2021
  ident: B33
  article-title: Blood Interferon-Alpha Levels and Severity, Outcomes, and Inflammatory Profiles in Hospitalized Covid-19 Patients
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.648004
– volume: 395
  year: 2020
  ident: B8
  article-title: Kawasaki-Like Disease: Emerging Complication During the COVID-19 Pandemic
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)31129-6
– volume: 3
  year: 2020
  ident: B26
  article-title: Endothelial Activation and Stress Index (EASIX) at Admission Predicts Fluid Overload in Recipients of Allogeneic Stem Cell Transplantation
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2020.01.028
– volume: 76
  year: 1998
  ident: B45
  article-title: Endothelial Dysfunction After Bone Marrow Transplantation: Increase of Soluble Thrombomodulin and PAI-1 in Patients With Multiple Transplant-Related Complications
  publication-title: Ann Hematol
  doi: 10.1007/s002770050364
– volume: 5
  year: 2020
  ident: B4
  article-title: Association of Cardiac Injury With Mortality in Hospitalized Patients With Covid-19 in Wuhan, China
  publication-title: JAMA Cardiol
  doi: 10.1001/jamacardio.2020.0950
– volume: 395
  year: 2020
  ident: B6
  article-title: Clinical Course and Risk Factors for Mortality of Adult Inpatients With COVID-19 in Wuhan, China: A Retrospective Cohort Study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)30566-3
– volume: 18
  year: 2020
  ident: B51
  article-title: Circulating Endothelial Progenitors are Increased in Covid-19 Patients and Correlate With SARS-CoV-2 RNA in Severe Cases
  publication-title: J Thromb Haemost
  doi: 10.1101/2020.04.29.20085878
– volume: 323
  year: 2020
  ident: B2
  article-title: Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China
  publication-title: JAMA
  doi: 10.1001/jama.2020.1585
– volume: 10
  start-page: 2045894020966547
  year: 2020
  ident: B34
  article-title: Circulating Markers of Angiogenesis and Endotheliopathy in COVID-19
  publication-title: Pulm Circ
  doi: 10.1177/2045894020966547
– volume: 35
  year: 2020
  ident: B13
  article-title: Endothelial Cell Infection and Endotheliitis in COVID-19
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)30937-5
– volume: 395
  year: 2020
  ident: B7
  article-title: An Outbreak of Severe Kawasaki-Like Disease at the Italian Epicentre of the SARS-CoV-2 Epidemic: An Observational Cohort Study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)31103-X
– volume: 11
  start-page: 42
  year: 2021
  ident: B30
  article-title: Polymorphisms in CXCR3 Ligands Predict Early CXCL9 Recovery and Severe Chronic GVHD
  publication-title: Blood Cancer J
  doi: 10.1038/s41408-021-00434-2
– volume: 64
  year: 2008
  ident: B39
  article-title: Generalized Maximally Selected Statistics
  publication-title: Biometrics
  doi: 10.1111/j.1541-0420.2008.00995.x
– volume: 25
  start-page: 30
  year: 2020
  ident: B40
  article-title: Laboratory Features of Severe vs. Non-Severe COVID-19 Patients in Asian Populations: A Systematic Review and Meta-Analysis
  publication-title: Eur J Med Res
  doi: 10.1186/s40001-020-00432-3
– volume: 31
  year: 2020
  ident: B43
  article-title: Platelet Functions and Activities as Potential Hematologic Parameters Related to Coronavirus Disease 2019 (Covid-19)
  publication-title: Platelets
  doi: 10.1080/09537104.2020.1762852
– volume: 172
  year: 2020
  ident: B1
  article-title: The Incubation Period of Coronavirus Disease 2019 (Covid-19) From Publicly Reported Confirmed Cases: Estimation and Application
  publication-title: Ann Intern Med
  doi: 10.7326/M20-0504
– volume: 19
  year: 2013
  ident: B29
  article-title: Endothelial Vulnerability and Endothelial Damage Are Associated With Risk of Graft-Versus-Host Disease and Response to Steroid Treatment
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2012.09.018
– volume: 148
  start-page: e175
  year: 2020
  ident: B41
  article-title: Risk Factors of Severe Cases With COVID-19: A Meta-Analysis
  publication-title: Epidemiol Infect
  doi: 10.1017/S095026882000179X
– volume: 58
  year: 2020
  ident: B42
  article-title: Lactate Dehydrogenase: An Old Enzyme Reborn as a COVID-19 Marker (and Not Only)
  publication-title: Clin Chem Lab Med
  doi: 10.1515/cclm-2020-1062
– volume: 92
  start-page: 95
  year: 2020
  ident: B22
  article-title: Predicting Sinusoidal Obstruction Syndrome After Allogeneic Stem Cell Transplantation With the EASIX Biomarker Panel
  publication-title: Haematologica
– volume: 50
  year: 2008
  ident: B36
  article-title: The Performance of Risk Prediction Models
  publication-title: Biom J
  doi: 10.1002/bimj.200810443
SSID ssj0000493335
Score 2.463138
Snippet The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has evoked a pandemic that challenges...
BackgroundThe coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has evoked a pandemic that...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 634416
SubjectTerms Adolescent
Adult
Aged
Aged, 80 and over
angiopoietin-2 (Ang-2)
Biomarkers - metabolism
COVID-19 - diagnosis
COVID-19 - mortality
EASIX
endothelial activation and stress index
Endothelial Cells - physiology
Female
Hematopoietic Stem Cell Transplantation
Hospitalization
Humans
Immunology
Male
Middle Aged
Prognosis
Prospective Studies
Respiration, Artificial
SARS-CoV-2 - physiology
SARS-CoV2 (COVID- 19)
Severity of Illness Index
soluble thrombomodulin
suppressor of tumorigenicity 2 (ST2)
Survival Analysis
Transplantation, Homologous
Treatment Outcome
Young Adult
Title EASIX for Prediction of Outcome in Hospitalized SARS-CoV-2 Infected Patients
URI https://www.ncbi.nlm.nih.gov/pubmed/34248931
https://www.proquest.com/docview/2550632795
https://pubmed.ncbi.nlm.nih.gov/PMC8261154
https://doaj.org/article/4b85aab98f1f4f79b81dd0b27c5e6c45
Volume 12
WOSCitedRecordID wos000670252800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1664-3224
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000493335
  issn: 1664-3224
  databaseCode: DOA
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1664-3224
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000493335
  issn: 1664-3224
  databaseCode: M~E
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3PaxQxFA5aKngpWn-t1RLBkxA7k2SSyXEtWyzUurha9haSTEJH2lnZH4I9-Lf7kuwuuyL20sswZDJM-N4L-R7vzfcQemssb3zlDVFNURFuKk-s9Io42HixYaF36V-YizN5fl6Px2q40eor1oRleeAM3BG3dWWMVXUoAw9SWSBYTWGpdJUXjif1UmA9G8HU98x7GWNVTmNCFKaOQnt9vYB4kJbvBQMOILYOoqTX_y-S-Xet5Mbhc_II7S1ZI-7n1T5G93y3jx7kPpK_nqCzQX90OsbAP_FwGjMvEW08CfjzYg4e5XHb4VWDkPbGN3jU_zIix5MLQvFpqsaCsWFWWJ09Rd9OBl-PP5JlmwTiuKjmpHS2CI2ByIcbAWTZU6asE7DRLPAbGajyrjQMboDdWOGdLZk1UYmtlGBCwZ6hnW7S-RcIF8IpaaijvgGIAhxdVeFqamRILdR5DxUrzLRbaojHVhZXGmKJCLNOMOsIs84w99C79Ss_soDG_yZ_iIZYT4za12kAPEIvPULf5hE99GZlRg17JSZATOcni5mG8AkYGZUK5jzPZl1_inEadXjKHpJbBt9ay_aTrr1MetwQoUVRo5d3sfgD9DDiEYvRKHuFdubThX-Ndt3PeTubHqL7clwfJleH66ffgz8d_APR
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=EASIX+for+Prediction+of+Outcome+in+Hospitalized+SARS-CoV-2+Infected+Patients&rft.jtitle=Frontiers+in+immunology&rft.au=Luft%2C+Thomas&rft.au=Wendtner%2C+Clemens-Martin&rft.au=Kosely%2C+Florentina&rft.au=Radujkovic%2C+Aleksandar&rft.date=2021-06-23&rft.eissn=1664-3224&rft.volume=12&rft.spage=634416&rft_id=info:doi/10.3389%2Ffimmu.2021.634416&rft_id=info%3Apmid%2F34248931&rft.externalDocID=34248931
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon